25th Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology

October 29-30, 2015
KEIO PLAZA HOTEL , Tokyo, Japan

FIRST AUTHOR INDEX
First Name	Last Name	No.	Title
Philip	D. Harvey	SL-1	Assessment and treatment of cognition and disability across psychiatric conditions
W. Wolfgang	Fleischhacker	SL-2	Pharmacological treatment of schizophrenia: Current issues and future perspectives
Hiroyuki	Uchida	S8-4	Antipsychotic dose and cognitive impairment
Tsuyoshi	Miyaoka	PJ-2	Efficacy and safety of Yokukansan in treatment-resistant schizophrenia: A Randomized, double-blind, placebo-controlled trial (A positive and negative syndrome scale, five-factor analysis)
Takashi	Tsuboi	EN-1	Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A Single-blind, randomized, controlled study
Tetsu	Tomita	EN-2	The Influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder
Fumihiko	Ueno	EN-3	Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression
W. Wolfgang	Fleischhacker	LS3	The management of adherence problems and the role of long-acting antipsychotics in the long-term treatment of schizophrenia
Philip	D. Harvey	LS5	Motivation and cognition in schizophrenia: Outcome and treatment implications
Hitoshi	Sakurai	O1A-1	Increasing Versus Maintaining the Dose of Olanzapine or Risperidone for Schizophrenia Patients Who Did Not Respond to Modest Dosage: A Double-Blind Randomized Controlled Trial
Takeo	Saito	O1A-5	Pharmacogenomic study of clozapine-induced agranulocytosis/granulocytopenia in a Japanese population
Norio	Furukori	O1B-3	Characteristics of escitalopram discontinuation syndrome: a preliminary study
Kazunari	Yoshida	O2C-6	Presence/absence of early improvement to antipsychotic treatment predicts subsequent treatment response/non-response in behavioral and psychological symptoms with dementia: Analysis of the CATIE-AD data
Shigeru	Toki	O2C-7	Big five personality, BIS and BAS as predictors for escitalopram treatment in patients with major depression
Miho	Ota	O2D-2	The effects of adjunctive intranasal oxytocin in patients with schizophrenia
Jyunichi	Iga	O2D-4	Association study of polymorphism in the serotonin transporter gene promoter, methylation profiles, and expression in patients with major depressive disorder
Nobutomo	Yamamoto	P1A-2	Inter-rater reliability and concurrent validity of the personal and social performance scale, Japanese version
Philip	D. Harvey	P1C-3	Dose effects for lurasidone treatment of cognitive impairments in schizophrenia
Cynthia	O. Siu	P1C-4	Long-term effects on daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia
Hikaru	Hori	P1D-2	Hiccups associated with switching fron olanzapine to aripiprazole in a patient with schizophrenia
Takashi	Watanabe	P1E-4	Impact of CYP2D6*10 polymorphism on the pharmacokinetics of mirtazapine and its desmethylated metabolite in Japanese patients treated with mirtazapine
Mitsuhiro	Tada	P1E-5	Antidepressant dose and treatment response in bipolar depression: Reanalysis of the systematic treatment enhancement program for bipolar disorder (STEP-BD) data
Masaaki	Ogasa	P1F-3	Treatment of depressive symptoms and improved functioning in schizophrenia
Yoshiteru	Takekita	P1F-5	Risperidone long-acting injection versus paliperidone palmitate for cognitive function in Japanese schizophrenia: a 6-month, open-label, randomized, pilot trial.
Yoshiteru	Takekita	P2C-2	Effect of the HTR7 polymorphisms on perospirone and aripiprazole efficacy for Japanese schizophrenia patients
Itaru	Miura	P2C-4	Influence of -141C Ins/Del polymorphism in DRD2 gene on clinical symptoms and plasma homovanillic acid levels in the treatment of schizophrenia with aripiprazole